A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
RATIONALE: Previous studies have shown that glucagon-like peptide-1 (GLP-1) agonists and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonists (tirzepatide) reduced severity of sleep apnea. However, whether these medications impact incid…
Semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has attracted significant global attention for its appetite-suppressing and weight-loss effects. Approved for pediatric use in child…
AIMS: To examine the impact of FDA approval of semaglutide (Wegovy) for chronic weight management on the utilization gap between males and females in the United States. MATERIALS AND METHODS: The study utilized 2019-2024 MarketScan commercial claims…
BACKGROUND: Obesity remains a major health challenge globally and in Asia, driving cardio-metabolic disease risks. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and mobile health (mHealth) coaching each demonstrate weight loss efficacy, but r…
PURPOSE: GLP-1 receptor agonists (GLP-1RAs) like semaglutide are effective for obesity treatment but may cause lean mass loss and post-discontinuation weight rebound. This study aimed to explore whether leucine supplementation alone or combined with…
Acquired hypothalamic obesity (aHO) is a disease characterized by rapid, clinically significant, and persistent weight gain resulting from damage to hypothalamic structures. aHO is associated with substantial morbidity, increased mortality, and marke…
Incretin therapies have emerged as key interventions for glycemic control and weight reduction and are now among Canada's costliest outpatient drug classes. This review synthesizes current clinical and economic evidence on the cost-effectiveness of i…
Metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of metabolic syndrome, has emerged as the leading cause of chronic liver disease worldwide. Its global prevalence estimated at 38% between 2016-2019, represen…
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely prescribed for type 2 diabetes mellitus and chronic weight management. With its growing global use, continuous pharmacovigilance is essential to detect emerging patterns of ad…
Obesity paradoxically increases sensitivity to immune checkpoint inhibitors (ICIs) despite elevating cancer risk, creating a clinical opportunity where metabolic dysfunction may generate a target-rich immune microenvironment. However, immunosuppressi…
Obesity is a chronic, multifactorial condition strongly associated with increased cardiovascular and metabolic risk, as well as the development of systemic complications. Recent evidence from randomized controlled trials-including SELECT, STEP-HFpEF,…
AIMS: The REALISED study assessed the clinical outcomes associated with oral semaglutide use in Thai patients with type 2 diabetes (T2D) in real-world clinical settings. MATERIALS AND METHODS: This retrospective, multi-centre cohort study included 19…
AIMS: To investigate the metabolic mechanisms underlying weight regain (WR) after semaglutide withdrawal in females with obesity, focusing on gut microbiota, bile acid metabolism, and central nervous system regulation. MATERIALS AND METHODS: In a pro…
Aim To evaluate the dynamic impact of an 8-month glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy with semaglutide on anthropometric metrics, blood lipid profiles, and adipokine status in obese patients, with and without type 2 diab…
Severe gastrointestinal intolerance with systemic complications can occur within hours of reinitiating high-dose semaglutide after a prolonged treatment interruption, even in patients who previously tolerated the medication. Elderly patients with com…
Ulcerative colitis (UC) often requires immunosuppressive therapy for remission. Glucagon-like peptide-1 receptor agonists are used for diabetes and obesity, although their role in UC is unclear. We report a 42-year-old woman with left-sided UC and po…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists have shown promise in managing type 2 diabetes mellitus (T2DM) and provide metabolic and cardiovascular benefits. Their associations with neurocognitive outcomes in clinical populations re…